VAXICAN

VAXICAN is a pioneering biotechnology research company dedicated to developing next-generation immunotherapeutics. Specializing in therapeutic cancer vaccines, VAXICAN employs a unique and novel platform of enveloped virus-like particles (Enveloped VLPs) designed to safely and effectively instruct and strengthen the patient's anticancer defense mechanisms.

Located in Gdansk, PL, VAXICAN's innovative VLP platform is supported by fully owned and in-house developed elements of machine learning (ML) and artificial intelligence (AI). Their approach involves the use of naturally occurring or genetically modified oncolytic viruses, utilizing an innovative antigen delivery method with insect models. VAXICAN VLP vaccines are engineered to present the extracellular domains of cancer antigens, mimicking viral infections to enhance antigen presentation through pathogen-associated molecular patterns (PAMPs).

This strategy stimulates a robust adaptive immune response, including the production of high-affinity antibodies and cytotoxic T cells, crucial for targeting tumor cells. VAXICAN is also active in modern whole viral and protein sequencing, operating as an Oxford Nanopore certified partner, specializing in bioinformatic analysis of full genomes. We invite the manager of VAXICAN to create a customized and exclusive company showcase and product listing on our platform.